Login to Your Account



Other News To Note


Monday, December 2, 2013
Geneuro SA, of Geneva, said its clinical program in schizophrenia was awarded more than $700,000 by the Stanley Medical Research Institute to support a clinical trial in schizophrenic patients with a monoclonal antibody targeting a protein, called Env, of endogenous retroviral origin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription